Katie Peng
About Katie Peng
Independent Class II director (term expires 2026); age 54; appointed February 2024. Chief Commercial Officer at Denali Therapeutics since September 2021; previously SVP Business Unit Head roles at Genentech (OMNI: neurology/ophthalmology/immunology/respiratory/rare disease; IMPACT) . Education: BA Biology (UC Berkeley) and MBA (Kelley School of Business, Indiana University) . Board deems her independent under Nasdaq and SEC rules; she serves on the Audit Committee .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Denali Therapeutics | Chief Commercial Officer | Sep 2021–present | Commercial leadership; management team member |
| Genentech | SVP, OMNI Business Unit Head | Nov 2019–Sep 2021 | Oversaw neurology, ophthalmology, immunology, respiratory, rare disease portfolio |
| Genentech | SVP, IMPACT Business Unit Head | Apr 2017–Oct 2019 | BU leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Adicet Bio, Inc. | Director | Current | Public company directorship |
Board Governance
- Classification and tenure: Class II director; term expires at 2026 annual meeting; director since February 2024 .
- Independence: Board determined all directors except CEO are independent; Audit Committee members meet SEC/Nasdaq independence standards .
- Committee assignments: Audit Committee member; chair is Joshua Reed; audit committee met 4 times in FY2024 .
- Attendance: Board met 8 times in 2024; each director attended ≥75% of aggregate board/committee meetings; all directors attended the 2024 annual meeting .
- Anti-hedging/pledging: Insider trading policy prohibits short sales, derivatives, hedging and pledging/margin accounts for directors .
Fixed Compensation
| Component | Amount/Terms | FY2024 Cash Received |
|---|---|---|
| Board annual cash retainer | $45,000 (revised Apr 9, 2024) | $43,805 (pro-rated for 2024 start) |
| Audit Committee member retainer | $10,000 | Included in fees earned |
| Meeting fees | Not applicable (policy uses retainers) | — |
| Chair fees | Not applicable (she is not chair) | — |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Grant Date Fair Value (FY2024 total) | Vesting |
|---|---|---|---|---|
| Stock Options (Initial) | Apr 2024 | 35,767 | Options: $439,866 (aggregate 2024) | Initial equity grant vests monthly over 3 years |
| RSUs (Initial) | Apr 2024 | 26,825 | Stock awards: $435,166 (aggregate 2024) | Initial equity grant vests monthly over 3 years |
| Stock Options (Annual) | Jun 2024 | 6,000 | Included in aggregate 2024 option FV | Annual grant vests fully at 1-year or next annual meeting |
| RSUs (Annual) | Jun 2024 | 4,500 | Included in aggregate 2024 stock FV | Annual grant vests fully at 1-year or next annual meeting |
- Director equity mix revised April 9, 2024 from 100% options to options+RSUs; initial grant cap $800,000; annual grant cap $400,000 .
- Performance metrics for director equity: Not applicable; director awards vest based on service (time-based) rather than performance conditions .
Other Directorships & Interlocks
| Company | Role | Interlock/Overlap | Notes |
|---|---|---|---|
| Adicet Bio, Inc. | Director | None disclosed with SRRK | Public biotech board role |
| Denali Therapeutics | Chief Commercial Officer | Denali is in SRRK’s 2024 compensation peer group | Katie is not on SRRK’s Compensation Committee (reduces direct influence) |
- Related-party transactions: Company reports no transactions >$120,000 involving directors/officers/five-percent holders since Jan 1, 2023, other than disclosed offerings; no transactions involving Ms. Peng are disclosed .
Expertise & Qualifications
- Commercial drug launch leadership; global commercialization expertise .
- Audit oversight experience via Audit Committee membership (financial literacy required; committee includes an SEC-designated financial expert as chair Joshua Reed) .
- Education: BA Biology (UC Berkeley) and MBA (Indiana University Kelley) .
Equity Ownership
| Metric | Amount | Notes |
|---|---|---|
| Beneficial ownership (total) | 35,573 shares | <1% of outstanding; breakdown below |
| Common shares owned | 8,680 | Direct ownership |
| Options exercisable within 60 days | 20,902 | Included in beneficial ownership |
| RSUs expected to vest within 60 days | 5,991 | Included in beneficial ownership |
| Options outstanding (Dec 31, 2024) | 41,767 | Director option holdings |
| RSUs outstanding (Dec 31, 2024) | 23,874 | Director RSU holdings |
- Pledging/hedging of company stock prohibited by policy (alignment positive) .
Governance Assessment
- Board effectiveness: Independent audit committee member; attendance threshold met; active participation in financial oversight (audit met 4x) supports governance quality .
- Pay and alignment: Director pay is standard for SRRK’s policy with a mix of cash retainers and time-based equity; ownership is modest (<1%); policy revisions added RSUs, which increase retention alignment without introducing performance metrics (typical for director compensation) .
- Conflicts: External executive role at Denali warrants monitoring because Denali is in SRRK’s compensation peer group; mitigating factor is she does not serve on SRRK’s Compensation Committee . No related-party transactions disclosed involving Ms. Peng .
- Red flags: None evident; no hedging/pledging; no attendance issues; no disclosed related-party transactions; indemnification and clawback policies in place at company level (clawback applies to executive incentive comp) .